CPH — Cipher Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- CA$204.91m
- CA$150.63m
- $21.16m
- 97
- 72
- 100
- 99
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.12 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -40.3% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.85 | ||
| Price to Tang. Book | 2.36 | ||
| Price to Free Cashflow | 9.4 | ||
| Price to Sales | 7.04 | ||
| EV to EBITDA | 9.73 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.42% | ||
| Return on Equity | 28.19% | ||
| Operating Margin | 47.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.45 | 21.61 | 21.94 | 20.68 | 21.16 | 21.34 | 21.67 | -1.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +118.7 | +48.47 | +16.44 | +202.18 | -22.34 | -47.99 | -6.47 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
Directors
- Craig Mull CHM
- Scott Langille CFO
- Diane Gajewczyk VPR
- Arthur Deboeck DRC
- John Mull DRC
- Cathy Steiner DRC
- Christian Godin IND
- Harold Wolkin IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 9th, 2004
- Public Since
- February 25th, 2004
- No. of Employees
- 6
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 24,107,316
- Address
- 5750 Explorer Drive,, Suite 404, MISSISSAUGA, L4W 0A9
- Web
- https://www.cipherpharma.com/
- Phone
- +1 9056025840
- Auditors
- RSM Canada LLP
Upcoming Events for CPH
Cipher Pharmaceuticals Inc Extraordinary Shareholders Meeting
Cipher Pharmaceuticals Inc Annual Shareholders Meeting
Cipher Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Cipher Pharmaceuticals Inc Earnings Release
Similar to CPH
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
Charlotte's Web Holdings
Toronto Stock Exchange
FAQ
What is the Cipher Pharmaceuticals share price?
As of Today at 19:05 UTC, shares in Cipher Pharmaceuticals are trading at CA$8.50. This share price information is delayed by 15 minutes.
How has the Cipher Pharmaceuticals share price performed this year?
Shares in Cipher Pharmaceuticals last closed at CA$8.50 and the price had moved by +150% over the past 365 days. In terms of relative price strength the Cipher Pharmaceuticals share price has outperformed the Toronto Stock Exchange 300 Composite Index by +137.23% over the past year.
What are the analyst and broker recommendations for Cipher Pharmaceuticals?
The overall consensus recommendation for Cipher Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cipher Pharmaceuticals dividend yield?
Cipher Pharmaceuticals does not currently pay a dividend.
Does Cipher Pharmaceuticals pay a dividend?
Cipher Pharmaceuticals does not currently pay a dividend.
When does Cipher Pharmaceuticals next pay dividends?
Cipher Pharmaceuticals does not currently pay a dividend.
How do I buy Cipher Pharmaceuticals shares?
To buy shares in Cipher Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cipher Pharmaceuticals?
As of the previous close price of CA$8.50, shares in Cipher Pharmaceuticals had a market capitalisation of CA$204.91m.
Where are Cipher Pharmaceuticals shares listed?
Here are the trading details for Cipher Pharmaceuticals:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: CPH
What kind of share is Cipher Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Cipher Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cipher Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Cipher Pharmaceuticals is CA$11.57. That is 36.07% above the last closing price of CA$8.50.
Analysts covering Cipher Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.42 for the next financial year.
What is the trend in the Cipher Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cipher Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +66.08%.
As of the last closing price of CA$8.50, shares in Cipher Pharmaceuticals were trading +51.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cipher Pharmaceuticals PE Ratio?
The Cipher Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 15.12. The shares last closed at CA$8.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cipher Pharmaceuticals?
Cipher Pharmaceuticals' management team is headed by:
- Craig Mull - CHM
- Scott Langille - CFO
- Diane Gajewczyk - VPR
- Arthur Deboeck - DRC
- John Mull - DRC
- Cathy Steiner - DRC
- Christian Godin - IND
- Harold Wolkin - IND